The mission of the Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) is to promote the early clinical development of promising therapies for the treatment of children, adolescents, and young adults with cancer and related disorders.
The Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) was founded in February 2003 by Dr. Tanya Trippett at Memorial Sloan-Kettering Cancer Center and Dr. Lia Gore at the University of Colorado Cancer Center to address the challenges of access of new therapies for children with cancer that has recurred. Using a think tank model to encourage innovative collaboration among physicians, scientists and other health care providers, a network specializing in treatment for children in North America whose cancer has failed to respond or recurred after standard treatment was created.
The consortium has evolved over 14 years from a clinical trials network to a research business enterprise with a strong research infrastructure that drives the development of innovative therapeutic strategies based upon the biology of the patient’s cancer.
Dr. Tanya Trippett
Co-Founder and Director
"I believe that it is our life’s commitment as well as responsibility to each child that we serve — as oncologists and researchers — to strive harder each day to have a better understanding of the complexity of childhood cancers and to leverage this knowledge, coupled with compassion, to bring hope by creation of a roadmap that leads to discovery and a cure for each child with cancer."
Dr. Tanya Trippett is a Board Certified Pediatric Hematologist Oncologist practicing at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City. She completed her medical and specialty training in Pediatrics at Duke University Medical Center. She completed her Fellowship and Chief Fellow appointment in Pediatric Hematology Oncology at MSKCC. She served in the US Air Force for 4 years where she served as Head of the Division of Pediatric Hematology and Oncology before returning to New York. Her areas of subspecialty expertise include the care of children with lymphoma as well as children with recurrent cancer who have failed standard treatment. She served as the Vice-Chairman of the Hodgkin Lymphoma Committee as well as the Chair of the Hodgkin Retrieval Committee of the Children’s Oncology Group for over a decade. Dr. Trippett has been named in Castle Connolly’s Top Doctors 2013-2017, Best Doctors 2013-2017, and is a Diamond Member of the International Association of Pediatricians and The Leading Physicians of the World appointed in 2010. She is the Director and Co-Founder of the Pediatric Oncology Experimental Therapeutics Investigators’ Consortium (POETIC), a collaborative network between multiple academic centers in North America specializing in cancer care to address the need for innovative biologically targeted treatment approaches for children with recurrent cancer.
Dr. Trippett created and co-founded her first 501(c)3 nonprofit charitable foundation, The POETIC Foundation, Inc. in 2011 designed to financially support new and innovative treatment initiatives for children with recurrent cancer in North America. With her knowledge of building programs and charities, she spearheaded the development of a second nonprofit organization, the Eugène Gasana Jr. Foundation, which she co-founded in 2013 and directs based on the vision of a patient with cancer to address healthcare disparities for children with cancer in Africa and other developing nations. She is presently leading a global humanitarian initiative to build an International Pediatric Cancer Center in Africa.